TRV130
Phase 3Completed 2 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Pain
Conditions
Acute Pain
Trial Timeline
Dec 1, 2015 → Aug 1, 2017
NCT ID
NCT02656875About TRV130
TRV130 is a phase 3 stage product being developed by Trevena for Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02656875. Target conditions include Acute Pain.
What happened to similar drugs?
20 of 20 similar drugs in Acute Pain were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02656875 | Phase 3 | Completed |
| NCT02520297 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Pain